+86-28-82633987
Synonym name: Sarsasapogenin 3-O-Beta-D-galactopyranosid
Catalogue No.: BP1394
Cas No.: 68422-00-4
Formula: C33H54O8
Mol Weight: 578.787
Botanical Source: dried rhizomes of Anemarrhena asphodeloides
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.
For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
117.8400
3.2807
3.2805
.0047
.7919
.6777
Low
76.2394
5.7080
No
No
No
No
No
No
0.3
Yes
No
No
No
Timosaponin A1 is a natural steroidal saponin derived from the traditional Chinese medicinal material Anemarrhena asphodeloides Bunge. In recent years, it has attracted much attention due to its multi-target pharmacological activity. As a natural product, Anemarinoma saponin A1 shows significant potential in anti-inflammation, anti-diabetic, and metabolic disease regulation, especially its inhibitory effects on 5-lipoxygenase (5-LO), cyclooxygenase-2 (COX-2), and dipeptidyl peptidase 4 (DPP-4), providing a theoretical basis for its application in chronic inflammation and diabetes treatment. This article will systematically review the chemical structure, physicochemical properties, sources, and extraction methods of anemarrhena saponin A1, delve into its pharmacological activity and mechanism of action, evaluate its druggability and pharmacokinetic characteristics, and look ahead to its clinical application prospects.
Anemarrhena saponin A1 has the chemical formula C36H58O10 and molecular weight of 578.7870, classifying it as a steroidal saponin compound. Its core structure is a steroid nucleus, connected by multiple glycosyl side chains, giving it high polarity. In terms of physicochemical properties, the LogP value of anemarmosaponin A1 is 3.2807, indicating moderate lipid solubility that facilitates cell membrane penetration; the polar surface area (TPSA) is 117.8400 Ų, reflecting its high molecular polarity, which may affect oral absorption and bioavailability. Low water solubility (0.0047 mg/mL) suggests limited solubility in the aqueous phase, suggesting that formulation optimization may be needed to improve bioavailability. Low blood-brain barrier penetration ability indicates limited distribution in the central nervous system, reducing potential CNS toxicity risk. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenicity test result was 0.3, indicating a low genotoxicity risk and a solid safety foundation.
Anemarrhena saponin A1 is mainly found in the rhizomes of Anemarrhena asphodeloides Bunge, a plant in the Liliaceae family. Anemarrhena is a traditional Chinese medicinal herb, widely used in formulas for clearing heat, moistening dryness, nourishing yin, and reducing fire. Its saponin components are among its main active components, and anemarrhena saponin A1, as a representative steroid saponin, is relatively abundant.
The extraction method typically uses solvent extraction combined with multi-stage separation and purification technology. Traditional extraction often uses ethanol or methanol aqueous solutions for reflux extraction of dried anemarrhena rhizomes, followed by liquid-liquid separation and column chromatography (such as silica gel columns, reversed-phase C18 columns), and other methods for separation and purification. In recent years, new technologies such as ultrasound-assisted extraction and microwave-assisted extraction have also been applied to improve extraction efficiency and purity. Purified anemarrhea saponin A1 can be analyzed qualitatively and quantitatively by high-performance liquid chromatography (HPLC) to ensure purity and inter-batch consistency.
Anemosaponin A1, as an inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase-2 (COX-2), has shown significant anti-inflammatory activity. 5-LO and COX-2 are key enzymes in the synthesis of inflammatory mediators, catalyzing the production of leukotrienes and prostaglandins, respectively, and participating in the regulation of inflammatory responses. The IC50 of anemarrhenamine saponin A1 for 5-LO was 3.29 μM, demonstrating strong enzyme inhibition ability; The IC50 for COX-2 inhibition was 36.43 μM, indicating moderate inhibition effectiveness. Animal model studies have shown that anemarrhea saponin A1 can significantly reduce inflammatory responses, lower levels of inflammatory factors, inhibit infiltration of inflammatory cells, and has potential anti-inflammatory therapeutic value.
The inhibitory effect of anemarrhedrin saponin A1 on dipeptidyl peptidase 4 (DPP-4) (IC50 33.25 μM) provides a molecular basis for its antidiabetic activity. DPP-4 is an important enzyme regulating insulin secretion and blood glucose homeostasis. Inhibiting DPP-4 can prolong the half-life of insulin enterostimule, promote insulin secretion, and improve glucose metabolism. In addition to DPP-4, anemarritis saponin A1 also exerts comprehensive regulatory effects by modulating various carbohydrate-related targets such as AMPK, SGLT2, GCK, PPARG, AKT1, IRS1, SLC2A4, PIK3R1, and INSR, improving insulin resistance, promoting glucose uptake and utilization, and lowering blood glucose levels. Both in vivo and in vitro experiments confirmed its hypoglycemic effect on diabetic model animals and protective effects on pancreatic islet β cells.
In addition to its anti-inflammatory and antidiabetic activities, anemarrhadrin saponin A1 also shows certain potential in antioxidant, antitumor, and neuroprotective aspects. By modulating oxidative stress-related signaling pathways, it alleviates cellular damage, inhibits tumor cell proliferation and migration, and exhibits multi-target, multi-pathway pharmacological characteristics.
The mechanism of action of anemarrhenia saponin A1 involves multiple signaling pathways and multiple molecular targets, reflecting its multi-target pharmacological characteristics.
By inhibiting 5-LO and COX-2, anemaritol saponin A1 reduces the production of inflammatory mediators leukotrienes and prostaglandins, thereby decreasing the intensity of inflammatory responses. Additionally, it can inhibit activation of the NF-κB signaling pathway, reduce the expression of inflammatory factors such as TNF-α, IL-1β, and IL-6, and alleviate tissue damage and inflammatory cell infiltration.
The inhibition of Zhimu saponin A1 on DPP-4 prolongs the duration of GLP-1 (glucagon-like peptide-1), promoting insulin secretion and recovery of β cell function. It activates the AMPK signaling pathway, enhances cellular energy metabolism, and promotes glucose uptake and lipid metabolism. By modulating key targets such as PPARγ, IRS1, and AKT1, it improves insulin signaling and alleviates insulin resistance. Additionally, inhibiting SGLT2 reduces renal glucose reabsorption, promotes urinary sugar excretion, and further lowers blood sugar.
Anemarthenaside A1 enhances cellular antioxidant capacity by regulating the Nrf2/ARE signaling pathway related to oxidative stress, protecting cells from oxidative damage. In tumor cells, it induces apoptosis and cycle arrest by inhibiting the PI3K/AKT/MTOR signaling pathway, thereby suppressing tumor growth.
The druggability evaluation of Anemarinal saponin A1 indicates that it has certain potential for drug development. The molecular weight is 578.7870, slightly above the upper limit of 500 Da recommended by Lipinski's rules, suggesting possible oral absorption limits. The LogP value is 3.2807, meeting the lipophilicity requirements for the drug and facilitating cell membrane penetration. TPSA is 117.8400, and moderate polarity may affect its penetration capability and bioavailability. Water solubility is relatively low, suggesting that formulation technology should be used to improve solubility.
The blood-brain barrier has low penetration capacity, reducing the risk of central nervous system toxicity but limiting its application in central nervous system diseases. The negative inhibition of the hERG channel and the low mutagenicity results of the Ames test indicate good safety.
Pharmacokinetics, existing studies show that anemaritol saponin A1 is absorbed orally slowly, has low bioavailability, and is mainly metabolized through the intestines and liver. It is widely distributed in the body, with main metabolic pathways including glycosidic bond hydrolysis and corresponding modification of the steroid parent nucleus. Excretion is mainly through bile and urine. In the future, further optimization of dosage forms and administration routes is needed to improve in vivo exposure and therapeutic efficacy.
As a multi-target natural steroid saponin, A1 has broad application prospects in anti-inflammatory and anti-diabetic fields. Its effective inhibition of 5-LO, COX-2, and DPP-4 provides a new strategy for combined treatment of chronic inflammatory diseases and diabetes. Especially in diabetes treatment, combined with regulation of metabolic-related targets such as AMPK and PPARγ, multidimensional blood glucose control and metabolic improvement are expected to be achieved.
However, Anemarrhenaside Saponin A1 still faces many challenges during clinical translation, including low water solubility and bioavailability limitations, metabolic complexity in vivo, and challenges in formulation development. Future research should focus on formulation improvements (such as nanocarriers, solid dispersions), pharmacokinetic optimization, and safety evaluation, while conducting systematic preclinical and clinical trials to verify efficacy and safety.
Additionally, the multi-target properties of anemarrhenamine saponin A1 suggest potential application value in metabolic syndrome, cardiovascular diseases, neurodegenerative diseases, and other fields, warranting further exploration and research.
Anemarinal saponin A1, as a natural steroid saponin with multi-target pharmacological activity, demonstrates its therapeutic potential in anti-inflammatory and anti-diabetic diseases. Its unique chemical structure and diverse mechanisms of action provide valuable examples for pharmacological research of natural products. Although its clinical application is still in its early stages, with continuous advances in extraction and purification technology, drug design, and formulation processes, Anemarthena saponin A1 is expected to become an important candidate for the development of novel natural drugs. Future research should strengthen systematic evaluation of its pharmacokinetics, toxicology, and clinical efficacy to move it from the laboratory to clinical practice and benefit more patients.
Shenshuai
Wenjing
Hedandan
